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Magnetic resonance spectroscopy (MRS) is a non-invasive technique to detect metabolites
within the normal and tumoral tissues. The ability of MRS to diagnose areas of high metabolic activity linked to tumor cell proliferation is particularly useful for radiotherapy treatment
planning because of better gross tumor volume (GTV) delineation.The GTV may be targeted
with higher radiation dose, potentially improving local control without excessive irradiation
to the normal adjacent tissues. Prostate cancer and glioblastoma multiforme (GBM) are
two tumor models that are associated with a heterogeneous tumor distribution. Preliminary
studies suggest that the integration of MRS into radiotherapy planning for these tumors is
feasible and safe. Image-guided radiotherapy (IGRT) by virtue of daily tumor imaging and
steep dose gradient may allow for tumor dose escalation with the simultaneous integrated
boost technique (SIB) and potentially decrease the complications rates in patients with
GBM and prostate cancers.
Keywords: MRS, IGRT, prostate cancer, GBM

POTENTIAL ADVANTAGES OF MAGNETIC RESONANCE
SPECTROSCOPY FOR FUNCTIONAL TUMOR IMAGING
Magnetic resonance spectroscopy (MRS) is based on nuclear
magnetic resonance technique to investigate the metabolism of
chemicals in the body. Different chemicals containing the same
nucleus exhibit characteristic chemical shifts in resonance frequency, allowing the chemical form of the element to be identified.
Since the most abundant atom in the body is hydrogen (H), 1 H
MRS estimates the concentration of different metabolites within
normal tissues of the body, which are displayed as a spectrum of
resonances (peaks) along the x-axis as parts per million (ppm) and
the amplitude of resonances is measured on the y-axis using an
arbitrary scale. Depending on the clinical question, many major
metabolites can be measured with MRS. In the brain, N -acetyl
aspartate (NAA) is a marker for neuronal and axonal integrity. A
decrease in NAA level is usually associated with neuronal loss or
damage. Choline (Cho) represents the constituents of cell membrane. Increased Cho is associated with increased concentration
of cells and or/cell membrane synthesis such as cancer. Creatinine (Cr) is a marker for cell energy metabolism. Decreased in
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Cr is associated with tissue death or necrosis. Lactate is a marker
for anaerobic glycolysis. Increased lactate is associated with hypoxemia and tumors because of their anaerobic metabolism. Increased
lipids concentration is observed in necrotic areas of the tumor.
In gliomas, NAA is reduced because of neurons destruction by
the tumor and Cho is increased because of tumor cell proliferation. Thus, abnormal Cho/NAA ratio is observed in areas of
tumor infiltration such as the area of vasogenic edema around the
gross tumor. Figure 1 illustrates the potential of MRS to outline
the gross tumor volume (GTV) in a patient with glioblastoma
multiforme (GBM).
Magnetic resonance spectroscopy is particularly helpful to
distinguish radiation injury from tumor recurrence after radiotherapy as both may have similar magnetic resonance imaging
(MRI) appearances (1). Decreased in Cho, NAA, and Cr are usually observed with radiation injury and high Cho/NAA ratio is
suggestive of tumor recurrence (2). In the prostate, Citrate (Cit)
is produced by the normal prostate epithelium. The prostate has
a high concentration of mitochondrial Zinc (Zn), which inhibits
aconitase, the first enzyme of the Krebs cycle, which normally
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FIGURE 1 | This patient with a glioblastoma multiforme shows the voxel
over the area of interest in the tumor over the sagittal T1 (A) and axial
FLAIR (B) image. Magnetic resonance spectroscopy (C) shows an elevated

converts citrate to isocitrate leading to a high concentration of
citrate in the prostatic epithelium (3). Cit is often decreased in
area of prostate adenocarcinoma because of the low Zn concentration. High Cho and Cr are also observed in tumor areas
because of cancer cells proliferation. Thus, higher Cho + Cr/Cit
ratio is observed in areas of high tumor concentration compared
to normal prostate tissue. Figure 2 illustrates the potential of
MRS to outline the GTV in a patient with biopsy-proven adenocarcinoma of the prostate. Interestingly, areas of high Gleason
score (4 + 3 or above) associated with tumor poor differentiation may be associated with high Cho + Cr/Cit ratio suggesting that MRS may be useful to guide prostate biopsy (4, 5). A
high Cho + Cr/Cit ratio is also associated with a large tumor
volume and advanced tumor stage (6, 7). As a result, MRS is
very accurate to detect high grade tumors within the prostate
gland, which may be useful for treatment planning because of
the high recurrence rates of these tumors (8). As prostate cancer has a heterogeneous distribution within the prostate gland,
MRS is particularly helpful to guide a second biopsy if the
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choline peak (single arrow) and decreased creatine (double arrow) and
N-acetyl aspartate (NAA) peaks (triple arrow), which is the typical pattern for
tumor (Images courtesy of Dr. Ashok Srinivasan, University of Michigan).

initial biopsy was negative among patients with a high PSA
level suspicious for prostate cancer (9). MRS can also be used
to assess radiotherapy response or recurrence following prostate
irradiation. As Cit level decreases following prostate cancer
irradiation at a faster rate than Cho or Cr, the Cho level, or Cho/Cr
ratio are often used for radiation response.
A low normalized Cho following radiotherapy may predict
a low PSA (0.5 ng/ml or less) at 1 year following prostate cancer treatment (10). Conversely, high Cho level or Cho/Cr ratio
may detect local recurrences in patients with rising PSA following
prostate cancer irradiation (11–13). The pattern of local recurrence following external beam irradiation of prostate cancer is
predominantly within the dominant intra-prostatic tumors suggesting that radiation dose escalation of these focal tumor masses
may improve local control (14).

PRINCIPLES OF IMAGE-GUIDED RADIOTHERAPY
Conventional treatment with three-dimensional conformal radiotherapy (3D-CRT) has been associated with a higher rate of toxicity
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FIGURE 2 | This patient has a biopsy-proven adenocarcinoma of the
prostate in the magnetic resonance spectroscopy area suspicious for
malignancy. Axial (A), Coronal (B), and sagittal (C) high-resolution

with radiation dose escalation because of irradiation of a large
volume of normal tissues (15). The introduction of intensitymodulated radiotherapy (IMRT) has led to significant reduction
of normal tissue irradiation because of the steep radiation dose
gradient away from the target volume compared to 3D-CRT (16).
However, a significant amount of normal tissues is still irradiated because the inclusion of the tumor and areas at high risk for
invasion with a large rim of normal tissue called planning target
volume or PTV to avoid marginal miss. Recently, image-guided
radiotherapy (IGRT) by combining the steep dose gradient of
IMRT with daily imaging may further improve treatment toxicity because of the PTV reduction provided that the gross tumor
and area at risk for tumor invasion can be accurately outlined
with proper diagnostic imaging (17). Functional tumor imaging
such as MRS in combination with conventional diagnostic studies such as MRI may allow the radiation oncologist to develop
a treatment plan that covers the PTV with a curative radiation
dose while sparing the normal organs with the simultaneous integrated boost (SIB) technique, which delivers different dose levels
within the PTV (18). Thus, the intra-prostatic or GBM GTV
outlined by MRS may be treated with a higher radiation dose
than the PTV for improved local control while the IMRT steep
dose gradient decreases radiation dose to the normal adjacent
organs and potentially reduces long-term complications. The success of functional imaging for accurate radiation delivery with
IGRT requires a close collaboration between the diagnostic radiologist and radiation oncologist as MRS is not easy to interpret
because of its limitations even for experienced diagnostic radiologist. As radiation dose escalation with IGRT may be associated with significant toxicity, it is imperative to outline the GTV
accurately.
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T2-weighted images. Axial diffusion weighted, b = 2000 (D) and ADC
map (E). 1H-spectroscopy demonstrating elevated choline/creatine-to-citrate
ratio (F).

POTENTIAL APPLICATION OF MRS FOR IGRT OF
GLIOBLASTOMA MULTIFORME
Multiple studies of radiation dose escalation for GBM have failed
to demonstrate an improvement in survival or local control (19).
However, these studies were based on 3D conformal radiotherapy
(3D-CRT) and MRI imaging. One possible explanation is whether
the high radiation dose was actually delivered to the areas of high
cancer concentration to be effective because of the heterogeneity of the tumor distribution within the target volume. Another
possible explanation is the protracted treatment time may not
be effective for local control because of the accelerated repopulation of cancer stem cells, which may be radio-resistant (20).
Thus, a treatment course that delivers a high radiation dose to
the GTV within a short time may be more effective for tumor
control and potentially improve patient quality of life as they will
have more time to spend with their family. Functional imaging
with MRS may allow the radiation oncologist to outline the target
volume accurately and spare the normal brain from unnecessary
irradiation. The potential of IGRT to decrease the planning target
volume (PTV) because of daily imaging coupled with the steep
dose gradient of IMRT may further reduce treatment toxicity. As
a result, the combination of precise tumor targeting and planning
with MRS and effective radiotherapy delivery through IGRT may
improve local control without excessive neurotoxicity. The feasibility of MRS for radiotherapy treatment planning of GBM has
been investigated. The choline to creatinine ratio as an indice of
the tumor activity (3 or higher) was converted on a gray scale,
fused to the MRI images and transferred to the computer tomography (CT) scan as GTV in 12 patients with glioma (21). Among
the patients in the study who had GBM, an IMRT plan was developed to delivered 5940 cGy in 180 cGy to the PTV while limiting
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radiation to the critical radiosensitive structures such as the optic
chiasm and brain stem. Radiotherapy treatment was well tolerated
by all patients without complications. A SIB plan was also generated but not used for treatment to increase the GTV dose to 7000
cGy based on the choline/creatinine ratio. Despite a higher GTV
dose, the dose to the radiosensitive structures did not increase
and highlighted the safety of radiation dose escalation with the
SIB technique. Another study corroborated the feasibility of MRS
for radiation dose escalation. Thirty-five GBM patients underwent surgical resection and had MRS to outline the tumor bed
after surgery (22). The voxels within the post-operative T2 MRI
that contained acholine/N -acetylaspartate ratio of 2 or above were
treated with stereotactic radiosurgery (SRS) to a dose determined
by the Radiation Therapy Oncology Group (RTOG) SRS guidelines followed by an additional dose of 6000 cGy with 3D-CRT.
Among the 16 patients of the study who received temozolomide
(TMZ) in addition to the radiotherapy protocol, median survival
was 20.8 months compared to the historical control of 14.6 months
for the ones treated with conventional radiotherapy and TMZ of
the European Organization for Research and Treatment of Cancer (EORTC) (23). Grade 3–4 toxicity of the protocol treatment
was acceptable suggesting that radiation dose-escalation based
on MRS for GTV delineation may improve local control without excessive toxicity. Preliminary studies of MRI-based IMRT
treatment of GBM also suggest that radiation dose escalation may
be safe when combined with TMZ. Thirty-eight GBM patients
were treated to a dose ranging from 6600 to 8100 cGy to the
GTV with the IMRT technique. Only three patients with radiation dose exceeding 7500 cGy developed radionecrosis. Among
the 22 patients who had functional imaging with C11 methionine positron emission tomography (MET–PET) before treatment,
seven out of eight patients recurred because of inadequate coverage
of the GTV as defined by MET–PET (24). This study highlights the
potential of MRS to avoid marginal miss and possibly decreasing
complications rates with PTV reduction. IMRT-based IGRT for
GBM has been investigated to shorten the treatment course with
promising results (25–27). Thus, MRS-based IGRT treatment for
GBM merits further investigations in the future to improve local
control and reduce toxicity.

POTENTIAL APPLICATION OF MRS FOR IGRT OF PROSTATE
CARCINOMA
On line IGRT in prostate cancer allows for immediate correction
of daily movement of the prostate secondary to bladder and rectum filling. The ability to increase radiation delivery accurately
avoids unnecessary irradiation of the bladder and rectum and
may decrease radiation side effects. In a study of 275 patients
with prostate cancer treated to a tumor dose of 74–78 Gy, patients
who had IGRT experienced significantly less diarrhea, urinary frequency, and fatigue compared to the ones without IGRT. The
margins and planning constraints were the same for both groups
(28). The reduced morbidity of radiation with daily imaging was
also corroborated in another study of 282 patients with prostate
cancer. Among 154 patients treated with IGRT, rectal pain and
diarrhea were significantly less even though they were treated
to a higher dose compared to the ones who did not have IGRT
(29). Inpatients with intermediate to high risk prostate cancer,
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a higher radiation dose may be required to improve local control and biochemical-free survival if dose escalation does not
lead to increased risk of complications (15). However, in patients
with multiple co-morbidity factors such as the elderly, increasing
radiation dose to the prostate may further increase the risk of rectal
damage because the close proximity of the rectum to the prostate
(30). Thus, increasing radiation dose to the intra-prostatic GTV
may offer the ideal solution of limiting rectal dose while delivering
a curative tumor dose. The feasibility of this treatment strategy
was demonstrated in a dosimetric study of eight patients with
prostate cancer (31). The intra-prostatic GTV as outlined with 18 F
Choline PET–CT, a cell proliferation marker with intense accumulation in prostatic cancer cell, was treated up to 90 Gy without
exceeding the dose constraints to the bladder and rectum with
the IMRT technique. Other dosimetric studies corroborated the
feasibility of PET-based GTV dose escalation up to 100 Gy with
IGRT for patients with prostate cancer (32, 33). The potential of
MRS for potential intra-prostatic GTV dose escalation with IMRT
was highlighted in one dosimetric study where the prostate was
treated to 70 Gy at 1.8 Gy/fraction while the GTV was treated to
90 Gy at 2.25 Gy (34). Compared to an IMRT plan that conventionally treated the prostate to 70 Gy, the rectal dose was 40 and 48 Gy
for the GTV dose escalation plan and conventional plan respectively. Thus, using MRS for potential GTV boost allows for a higher
radiobiologic dose to the tumor while decreasing radiation dose
to the rectum.
The safety of intra-prostatic GTV dose escalation was illustrated in a clinical study of 118 patients with intra-prostatic GTV
defined either on MRI or MRS (35). The GTV and PTV were
treated to 81–82 and 78 Gy, respectively with IMRT. No patient
developed grade 3–4 gastrointestinal toxicity. Figure 3 illustrates
the potential of MRS for GTV boost in a patient with prostate adenocarcinoma treated with radical prostatectomy (36). The patient
had two intra-prostatic nodules suggestive of malignancy on preoperative MRS and confirmed pathologically after surgery. These
two GTV could have been treated to a high radiation dose to
improve local control while sparing the rectum if the patient had
definitive irradiation instead of surgery. In fact, this patient may be
a good candidate for high dose rate prostate brachytherapy as these
two foci can be treated to a higher dose by increasing the dwell time
of the radioactive source (37). Preliminary clinical study of PETbased intra-prostatic GTV dose escalation with IGRT has been
very promising because of minimal toxicity (38). As 18 F-choline
PET–CT may not be available in most centers, MRS-based GTV
may be a practical method for IGRT dose escalation of prostate
cancer. MRS may also play a significant role in the future because
of its ability to detect recurrence following external beam prostate
irradiation and for possible salvage (39).

LIMITATIONS OF MAGNETIC RESONANCE SPECTROSCOPY
Multiple factors can potentially limit MRS. Inhomogeneities in
the magnetic field can cause peak overlap and poor quantification. This can be limited if the magnetic field is shimmed prior to
the MRS study, which helps to correct for magnetic field inhomogeneities. Susceptibility artifact can degrade the study if the area
of interest is in a part of the brain close to bone or air, such as
in the paranasal sinuses. Iron and other minerals built up in the
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FIGURE 3 | This patient had a radical prostatectomy
demonstrating two intra-prostatic adenocarcinoma in the
pre-operative magnetic resonance spectroscopy areas suspicious
for malignancy. These two gross tumor volumes could have been
treated to a higher radiation dose (81 Gy) while the prostate received
only 78 Gy with the image-guided radiotherapy technique, thus
improving the chance for local control and decreasing the risk of

paranasal ganglia can also cause susceptibility artifact that causes
distorsion. In a similar fashion, if the spectrum is obtained in an
area of the brain close to the scalp, scalp lipids can degrade the
spectrum. Each box in an MRS exam called a voxel, is limited
in spatial selectivity, and when using multivoxel MRS technique,
there is a certain degree of overlap within each voxel from the
adjacent voxels. In general, spatial resolution is also limited due to
a low signal to noise ratio.

CONCLUSION
Functional imaging with MRS may allow radiation dose escalation with IGRT for GBM and prostate carcinoma while sparing
the adjacent normal organs. MRS should be integrated in future
prospective studies to assess its potential to reduce long-term complications and possibly improving local control in patients with
GBM and prostate cancers.
REFERENCES
1. Huang J, Wang AM, Shetty A, Maitz AH, Yan D, Doyle D, et al. Differentiation
between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling. Magn Reson
Imag (2011) 29:993–1001. doi:10.1016/j.mri.2011.04.004
2. Elias AE, Carlos RC, Smith EA, Frechtling D, George B, Maly P, et al. MR
spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury. Acad Radiol (2011)
18:1101–8. doi:10.1016/j.acra.2011.05.006
3. Costello LC, Franklin RB. Concepts of citrate production and secretion by
prostate: hormonal relationships in normal and neoplastic prostate. Prostate
(1991) 19:181–205. doi:10.1002/pros.2990190302
4. Brames R, Zaider M, Zakian KL, Koutcher JA, Shukla-Dave A, Reuter VE, et al.
Regarding the focal treatment of prostate cancer: inference of the Gleason grade
from magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys
(2009) 74:110–4. doi:10.1016/j.ijrobp.2008.07.055
5. Kobus T, Vos PC, Hambrock T, De Rooj M, Hulsbergen-Van de Kaa CA, Barentsz JO, et al. Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3T. Radiology (2012) 265:457–67.
doi:10.1148/radiol.12111744

www.frontiersin.org

MRS and IGRT

long-term rectal damage. (A) The areas outlined in red showed the
cancerous tissue in the right and left lobe in the prostate. (B) The
areas outlined in orange had an abnormal CCr (choline+creatine/
citrate) ratio suspicious for malignancy on pre-operative magnetic
resonance spectroscopy. (Images courtesy of Dr. Shigeo Horie, Teikyo
University, and Dr. John G. Delinasios, International Institute of
Anticancer Research.)

6. Creange G, Parfait S, Liegard M, Maingon P, Ben Salem D, Cochet A, et al. Tumor
volume and metabolism of prostate cancer determined by proton magnetic resonance spectroscopic imaging at 3T without endorectal coil reveal potential
clinical implications in the context of radiation oncology. Int J Radiat Oncol Biol
Phys (2011) 80:1087–94. doi:10.1016/j.ijrobp.2010.03.007
7. Shukla-Dave A, Hricak H, Ishill NM, Moskowitz CS, Drobnjak M, Reuter VE,
et al. Correlation of MR imaging and MR spectroscopic imaging findings with
Ki-67, phospho-AKT, and androgen receptor expression in prostate cancer. Radiology (2009) 250:803–12. doi:10.1148/radiol.2503080473
8. Villeirs GM, de Meerleer GO, de Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the
assessment of high grade prostate carcinoma in patients with elevated PSA: a
single institution experience of 356 patients. Int J Radiat Oncol Biol Phys (2009)
77:340–5. doi:10.1016/j.ejrad.2009.08.007
9. Panebianco V, Sciarra A, Ciccarielllo M, Lisi D, Bernado S, Cattarino S, et al.
Role of magnetic resonance spectroscopic imaging ([1 H]MRSI) and dynamic
contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in
patients with negative biopsy and high levels of prostate specific antigens. Radiol
Med (2010) 115:1314–29. doi:10.1007/s11547-010-0575-3
10. Menard C, Smith ICP, Somorjai RL, Leboldus L, Patel R, Littman C, et al. Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy:
a histopathologic study of diagnostic validity. Int J Radiat Oncol Biol Phys (2001)
50:317–23. doi:10.1016/S0360-3016(01)01480-8
11. Pucar D, Shukla D, Hricak H, Moskowitz CS, Kuroiwa K, Olgac S, et al. Prostate
cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology (2005) 236:545–53.
doi:10.1148/radiol.2362040739
12. Valentini AL, Gui B, d’Agostino GR, Mattiuci G, Clementi V, di Molfetta IV, et al.
Locally advanced prostate cancer: three-dimensional magnetic resonance spectroscopy to monitor prostate response to radiotherapy. Int J Radiat Biol Phys
(2011) 84:719–24. doi:10.1016/j.ijrobp.2011.12.089
13. Westphalen AC, Coakley FV, Roach M, McCulloch CE, Kurhanewizc J. Locally
recurrent prostate cancer after external beam radiation therapy. Radiology
(2010) 256:485–92. doi:10.1148/radiol.10092314
14. Arrayeh E, Westphalen AC, Kurhanewicz J, Roach M, Jung AJ, Carrrol PR,
et al. Does local recurrence of prostate cancer after radiation therapy occur
at the site of the primary tumor? Results of a longitudinal MRI and MRS
study. Int J Radiat Oncol Biol Phys (2011) 82:e787–93. doi:10.1016/j.ijrobp.2011.
11.030
15. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al.
Long-term results of the M.D.Anderson randomized dose-escalation trial for

May 2014 | Volume 4 | Article 91 | 5

Nguyen et al.

prostate cancer. Int J Radiat Oncol Biol Phys (2008) 70:67–74. doi:10.1016/j.
ijrobp.2007.06.054
16. Gupta T, Agarwall J, Jain S, Phurailatpam R, Kannan S, Ghosh-Laskar S,
et al. Three-dimensional conformal radiotherapy (3D-CRT) versus intensitymodulated radiotherapy (IMRT) in squamous cell carcinoma of the head
and neck: a randomized controlled trial. Radiother Oncol (2012) 104:343–8.
doi:10.1016/j.radonc.2012.07.001
17. Louvel G, Cazoulat G, Chazon E, Le Maitre A, Simon A, Henry O, et al.
Image-guided and adaptive radiotherapy. Cancer Radiother (2012) 16:423–9.
doi:10.1016/j.canrad.2012.07.177
18. Leclerc M, Maingon P, Hamoir P, Dalban C, Calais G, Nuyts S, et al. A dose escalation study with intensity modulated radiotherapy (IMRT) in T2N0, T2N1, T3N0
squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx
using a simultaneous integrated boost (SIB) approach. Radiother Oncol (2013)
106:333–40. doi:10.1016/j.radonc.2013.03.002
19. Souhami L, Seiferheld W, Brachman D, Podgorsack EB, Werner-Wasik M, Lustig
R, et al. Randomized comparison of stereotactic radiosurgery with Carmustine for patients with glioblastoma multiforme: report of radiation therapy
oncology group 93-05 protocol. Int J Radiat Oncol Biol Phys (2004) 60:856–60.
doi:10.1016/j.ijrobp.2004.04.011
20. Gao X, McDonald JT, Hlatky L, Enderling H. Acute and fractionated irradiation
differentially modulate glioma stem cell division kinetics. Cancer Res (2013)
73:1481–90. doi:10.1158/0008-5472.CAN-12-3429
21. Narayana A, Chang J, Thakur S, Huang W, Karimi S, Hou B, et al. Use of MR
spectroscopy and functional imaging in the treatment of glioma. Br J Radiol
(2007) 80:347–54. doi:10.1259/bjr/65349468
22. Einstein DB, Wessels B, Bangert B, Fu P, Nelson AD, Cohen M, et al. Phase II trial
of radiosurgery to magnetic resonance spectroscopy-defined high risk tumor
volumes in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys
(2012) 84:668–74. doi:10.1016/j.ijrobp.2012.01.020
23. Stupp R, Heqi ME, Mason WP, van den Bent MJ, Taphoom MJ, Janger RC,
et al. Effect of radiotherapy with concomitant and adjuvant temozolamide versus radiotherapy alone on survival in glioblastoma in a randomized phase III
study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 10:459–66.
doi:10.1016/S1470-2045(09)70025-7
24. Tsien CI, Brown D, Normolle D, Schipper M, Piert M, Junck L, et al. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy
in newly diagnosed glioblastoma. Clin Cancer Res (2012) 18:273–9. doi:10.1158/
1078-0432.CCR-11-2073
25. Lipani JD, Jackson PS, Soltys SG, Sato K, Adler JR. Survival following Cyberknife radiosurgery and hypofractionated radiotherapy for newly
diagnosed glioblastoma multiforme. Technol Cancer Res Treat (2008) 7:
249–55.
26. Sato K, Baba Y, Inoue M, Omori R. Radiation necrosis and brain edema associated with cyberknife treatment. Acta Neurochir Suppl (2003) 86:513–6.
27. Yoshikawa K, Saito K, Kajiwara K, Nomura S, Ishihara H, Suzuki M. Cyberknife
stereotactic radiotherapy for patients with malignant glioma. Min Invasive Neurosurg (2006) 49:110–5. doi:10.1055/s-2006-932183
28. Gill S, Thomas J, Fox C, Kron T, Rolfo A, Leahy M, et al. Acute toxicity in
prostate cancer patients treated with and without image-guided radiotherapy.
Radiat Oncol (2011) 6:145. doi:10.1186/1748-717X-6-145
29. Singh J, Greer PB, White MA, Parker J, Patterson JP, Tang CI, et al. Treatmentrelated morbidity in prostate cancer: a comparison of 3-dimensional conformal
radiotherapy with and without image guidance using implanted fiducial markers. Int J Radiat Oncol Biol Phys (2012) 85:1018–23. doi:10.1016/j.ijrobp.2012.
07.2376
30. Hamstra DA, Stenmark MH, Ritter T, Litzenberg D, Jackson W, Johnson S,
et al. Age and comorbid illness are associated with late rectal toxicity following

Frontiers in Oncology | Radiation Oncology

MRS and IGRT

31.

32.

33.

34.

35.

36.

37.

38.

39.

dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys
(2013) 85:1246–53. doi:10.1016/j.ijrobp.2012.10.042
Chang JH, Joon DL, Lee ST, Gong SV, Anderson NJ, Scott AM, et al. Intensity modulated radiation dose painting for localized prostate cancer using 11 C
choline positron emission tomography plan. Int J Radiat Oncol Biol Phys (2012)
83:e691–6. doi:10.1016/j.ijrobp.2012.01.087
Hardcastle N, Tome WA. Risk-adaptive volumetric modulated arc therapy using
biologic objective functions for subvolume boosting in radiotherapy. Comput
Math Methods Med (2012) 2012:348471. doi:10.1155/2012/348471
Maggio A, Fiorino C, Mangili P, Cozzarini C, de Cobelli F, Cattaneo GM, et al.
Feasibility of safe ultra-high (EQD2>100 Gy) dose escalation on dominant
intra-prostatic lesions by helical tomotherapy. Acta Oncol (2011) 50:25–34.
doi:10.3109/0284186X.2010.530688
Pickett B, Vigneaut E, Kurhanewicz J, Verhey L, Roach M. Static field intensity
modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to
seven fields 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys (1999)
43:921–9. doi:10.1016/S0360-3016(98)00502-1
Fonteyne V, Villeirs G, Speelers B, de Neve W, de Wagter C, Lumen N,
et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated
boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys (2008) 72:799–807.
doi:10.1016/j.ijrobp.2008.01.040
Saito K, Kaminaga T, Muto S, Ide H. Clinical efficacy of proton magnetic resonance spectroscopy (1 H-MRS) in the diagnosis of prostate cancer. Anticancer
Res (2008) 28:1899–904.
Kazi A, Godwin G, Simpson J, Sasso G. MRS-guided HDR brachytherapy boost
to the dominant intraprostatic lesion in high risk localized prostate cancer. BMC
Cancer (2010) 10:472. doi:10.1186/1471-2407-10-472
Pinkawa M, Piroth MD, Holy R, Klotz J, Djukic V, Corral NE, et al.
Dose-escalation using intensity-modulated radiotherapy for prostate cancerevaluation of quality of life with and without (18)F-choline PET-CT detected
simultaneous integrated boost. Radiat Oncol (2012) 7:14. doi:10.1186/1748717X-7-14
Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IG, Dea R, et al. Feasibility of MRI
imaging/MR-spectroscopy-planned focal partial salvage permanent prostate
implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int
J Radiat Oncol Biol Phys (2012) 85:370–7. doi:10.1016/j.ijrobp.2012.04.028

Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 10 October 2013; accepted: 14 April 2014; published online: 05 May 2014.
Citation: Nguyen ML, Willows B, Khan R, Chi A, Kim L, Nour SG, Sroka T,
Kerr C, Godinez J, Mills M, Karlsson U, Altdorfer G, Nguyen NP, Jendrasiak G
and The International Geriatric Radiotherapy Group (2014) The potential role of
magnetic resonance spectroscopy in image-guided radiotherapy. Front. Oncol. 4:91.
doi:10.3389/ fonc.2014.00091
This article was submitted to Radiation Oncology, a section of the journal Frontiers in
Oncology.
Copyright © 2014 Nguyen, Willows, Khan, Chi, Kim, Nour, Sroka, Kerr, Godinez,
Mills, Karlsson, Altdorfer, Nguyen, Jendrasiak and The International Geriatric Radiotherapy Group. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.

May 2014 | Volume 4 | Article 91 | 6

